Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Long-Term Capital Lease Obligation : ¥2 Mil (As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Tianjin Pharmaceutical Da Ren Tang Group Long-Term Capital Lease Obligation?

Tianjin Pharmaceutical Da Ren Tang Group's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥2 Mil.

Tianjin Pharmaceutical Da Ren Tang Group's quarterly Long-Term Capital Lease Obligation increased from Sep. 2023 (¥1 Mil) to Dec. 2023 (¥3 Mil) but then declined from Dec. 2023 (¥3 Mil) to Mar. 2024 (¥2 Mil).

Tianjin Pharmaceutical Da Ren Tang Group's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (¥2 Mil) to Dec. 2022 (¥1 Mil) but then increased from Dec. 2022 (¥1 Mil) to Dec. 2023 (¥3 Mil).

Tianjin Pharmaceutical Da Ren Tang Group Long-Term Capital Lease Obligation Historical Data

The historical data trend for Tianjin Pharmaceutical Da Ren Tang Group's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianjin Pharmaceutical Da Ren Tang Group Long-Term Capital Lease Obligation Chart

Tianjin Pharmaceutical Da Ren Tang Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

2.71

1.71

1.57

0.87

2.74

Tianjin Pharmaceutical Da Ren Tang Group Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.58	0.61	0.60	2.74	2.30

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Tianjin Pharmaceutical Da Ren Tang Group Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Tianjin Pharmaceutical Da Ren Tang Group's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd (SHSE:600329) » Definitions » Long-Term Capital Lease Obligation

Traded in Other Exchanges

T14:Singapore

Address

No. 17 Baidi Road, Zhong Xin Mansion, Nankai District, Tianjin, CHN, 300193

Website

http://www.jydrt.com.cn

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments namely The Chinese Medicine segment and The Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Headlines

No Headlines